Krystal BiotechKRYS
KRYS
About: Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Employees: 275
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
207% more call options, than puts
Call options by funds: $54.2M | Put options by funds: $17.6M
117% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 29
17% more funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 7 (+1) [Q1 2025]
13% more capital invested
Capital invested by funds: $4.35B [Q4 2024] → $4.92B (+$573M) [Q1 2025]
12% more funds holding
Funds holding: 263 [Q4 2024] → 295 (+32) [Q1 2025]
1.76% less ownership
Funds ownership: 96.57% [Q4 2024] → 94.81% (-1.76%) [Q1 2025]
22% less repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 111
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$155
13%
upside
Avg. target
$201
46%
upside
High target
$240
75%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
Citigroup Yigal Nochomovitz | 13%upside $155 | Neutral Maintained | 16 May 2025 |
Guggenheim Debjit Chattopadhyay | 38%upside $189 | Buy Maintained | 7 May 2025 |
Chardan Capital Geulah Livshits | 60%upside $219 | Buy Maintained | 7 May 2025 |
HC Wainwright & Co. Joseph Pantginis | 75%upside $240 | Buy Reiterated | 6 May 2025 |
Financial journalist opinion
Negative
Zacks Investment Research
1 week ago
Why Is Krystal Biotech (KRYS) Down 3.5% Since Last Earnings Report?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Positive
MarketBeat
1 month ago
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn't Ignore
Investors searching for high-quality opportunities in the pharmaceutical space should keep a close eye on stocks trading at extremely oversold levels. One of the most popular ways to measure this is through the Relative Strength Index (RSI), a technical momentum indicator that signals when a stock may be due for a rebound.
Neutral
GlobeNewsWire
1 month ago
Krystal Biotech to Present at BofA Securities 2025 Health Care Conference
PITTSBURGH, May 07, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference on May 14, 2025, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 11:20 am PT and host investor meetings throughout the day.
Neutral
Seeking Alpha
1 month ago
Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript
Krystal Biotech, Inc. (NASDAQ:KRYS ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Stephane Paquette - VP, Corporate Development Krish Krishnan - Chairman and CEO Suma Krishnan - President, Research and Development Jennifer McDonough - SVP, Patient Access, Analytics and Operations Christine Wilson - SVP and Head, U.S. Sales and Marketing Kate Romano - CAO Conference Call Participants Alec Stranahan - Bank of America Roger Song - Jefferies Ritu Baral - TD Cowen Gavin Clark-Gartner - Evercore ISI Sami Corwin - William Blair Andrea Newkirk - Goldman Sachs Debjit Chattopadhyay - Guggenheim Securities Yigal Nochomovitz - Citigroup Operator Thank you for standing by, and welcome to the Krystal Biotech First Quarter 2025 Earnings Call. At this time, all participants are on a listen-only mode.
Negative
Zacks Investment Research
1 month ago
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down
KRYS reports disappointing first-quarter 2025 results, with both earnings and sales missing estimates. Shares down.
Negative
Zacks Investment Research
1 month ago
Krystal Biotech, Inc. (KRYS) Misses Q1 Earnings and Revenue Estimates
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.20 per share, missing the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $0.03 per share a year ago.
Neutral
Zacks Investment Research
1 month ago
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
1 month ago
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional PITTSBURGH, April 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that on April 23, 2025, the European Commission (EC) granted marketing authorization to VYJUVEK® (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. VYJUVEK is designed to address the genetic root cause of DEB by delivering functional copies of the human COL7A1 gene to provide wound healing and sustained functional type VII collagen protein expression with redosing.
Neutral
GlobeNewsWire
1 month ago
Krystal Biotech to Present at Upcoming Scientific Conferences
PITTSBURGH, April 24, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs in the lung, eye, and skin at upcoming scientific conferences being held in May and June.
Neutral
GlobeNewsWire
2 months ago
Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer
PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an extensive track record of building innovative companies as well as launching and commercializing leading brands, including BOTOX®, one of the most widely recognized global brands. Mr. Forth has also served as a valuable contributor on Jeune's board of directors since February 2021.
Charts implemented using Lightweight Charts™